Follicular development in a 7-day versus 4-day hormone-free interval with an oral contraceptive containing 20 mcg ethinyl estradiol and 1 mg norethindrone acetate

Combined oral contraceptive (COC) formulations with 20 mcg ethinyl estradiol (EE) have a greater incidence of ovarian hormone production and follicular development, which can be managed by shortening the number of hormone-free days per COC cycle. This study evaluates differences in follicular develo...

Full description

Saved in:
Bibliographic Details
Published inContraception (Stoneham) Vol. 79; no. 3; pp. 182 - 188
Main Authors Rible, Radhika D., Taylor, DeShawn, Wilson, Melissa L., Stanczyk, Frank Z., Mishell, Daniel R.
Format Journal Article
LanguageEnglish
Published New York, NY Elsevier Inc 01.03.2009
Elsevier
Subjects
Online AccessGet full text
ISSN0010-7824
1879-0518
1879-0518
DOI10.1016/j.contraception.2008.10.005

Cover

Abstract Combined oral contraceptive (COC) formulations with 20 mcg ethinyl estradiol (EE) have a greater incidence of ovarian hormone production and follicular development, which can be managed by shortening the number of hormone-free days per COC cycle. This study evaluates differences in follicular development during a 7-day versus 4-day hormone-free interval in a COC regimen with 20 mcg EE and 1 mg norethindrone acetate. Forty-one healthy women were randomized in an open-label fashion to this formulation in either a 24/4 or a 21/7 day regimen for three cycles. Estradiol, progesterone, follicle-stimulating hormone, luteinizing hormone and inhibin B were measured daily from Cycle 2, Day 21 to Cycle 3, Day 3 and on Day 7 of Cycle 3. Follicular diameter and Hoogland score were calculated on Cycle 2, Days 21, 24 and 28 and Cycle 3, Days 3 and 7. Sixty-six percent of subjects in the 21/7 group and 70% of the subjects in the 24/4 group developed a follicle greater than 10 mm diameter. Ovarian steroid hormone levels, Hoogland scores and bleeding patterns were not statistically significant between the groups. In contrast to prior studies, this analysis suggests no difference in follicle development or bleeding patterns among women receiving a 21/7 or 24/4 regimen of a 20-mcg EE/1-mg norethindrone acetate COC.
AbstractList Combined oral contraceptive (COC) formulations with 20 mcg ethinyl estradiol (EE) have a greater incidence of ovarian hormone production and follicular development, which can be managed by shortening the number of hormone-free days per COC cycle. This study evaluates differences in follicular development during a 7-day versus 4-day hormone-free interval in a COC regimen with 20 mcg EE and 1 mg norethindrone acetate.BACKGROUNDCombined oral contraceptive (COC) formulations with 20 mcg ethinyl estradiol (EE) have a greater incidence of ovarian hormone production and follicular development, which can be managed by shortening the number of hormone-free days per COC cycle. This study evaluates differences in follicular development during a 7-day versus 4-day hormone-free interval in a COC regimen with 20 mcg EE and 1 mg norethindrone acetate.Forty-one healthy women were randomized in an open-label fashion to this formulation in either a 24/4 or a 21/7 day regimen for three cycles. Estradiol, progesterone, follicle-stimulating hormone, luteinizing hormone and inhibin B were measured daily from Cycle 2, Day 21 to Cycle 3, Day 3 and on Day 7 of Cycle 3. Follicular diameter and Hoogland score were calculated on Cycle 2, Days 21, 24 and 28 and Cycle 3, Days 3 and 7.STUDY DESIGNForty-one healthy women were randomized in an open-label fashion to this formulation in either a 24/4 or a 21/7 day regimen for three cycles. Estradiol, progesterone, follicle-stimulating hormone, luteinizing hormone and inhibin B were measured daily from Cycle 2, Day 21 to Cycle 3, Day 3 and on Day 7 of Cycle 3. Follicular diameter and Hoogland score were calculated on Cycle 2, Days 21, 24 and 28 and Cycle 3, Days 3 and 7.Sixty-six percent of subjects in the 21/7 group and 70% of the subjects in the 24/4 group developed a follicle greater than 10 mm diameter. Ovarian steroid hormone levels, Hoogland scores and bleeding patterns were not statistically significant between the groups.RESULTSSixty-six percent of subjects in the 21/7 group and 70% of the subjects in the 24/4 group developed a follicle greater than 10 mm diameter. Ovarian steroid hormone levels, Hoogland scores and bleeding patterns were not statistically significant between the groups.In contrast to prior studies, this analysis suggests no difference in follicle development or bleeding patterns among women receiving a 21/7 or 24/4 regimen of a 20-mcg EE/1-mg norethindrone acetate COC.CONCLUSIONIn contrast to prior studies, this analysis suggests no difference in follicle development or bleeding patterns among women receiving a 21/7 or 24/4 regimen of a 20-mcg EE/1-mg norethindrone acetate COC.
Combined oral contraceptive (COC) formulations with 20 mcg ethinyl estradiol (EE) have a greater incidence of ovarian hormone production and follicular development, which can be managed by shortening the number of hormone-free days per COC cycle. This study evaluates differences in follicular development during a 7-day versus 4-day hormone-free interval in a COC regimen with 20 mcg EE and 1 mg norethindrone acetate. Forty-one healthy women were randomized in an open-label fashion to this formulation in either a 24/4 or a 21/7 day regimen for three cycles. Estradiol, progesterone, follicle-stimulating hormone, luteinizing hormone and inhibin B were measured daily from Cycle 2, Day 21 to Cycle 3, Day 3 and on Day 7 of Cycle 3. Follicular diameter and Hoogland score were calculated on Cycle 2, Days 21, 24 and 28 and Cycle 3, Days 3 and 7. Sixty-six percent of subjects in the 21/7 group and 70% of the subjects in the 24/4 group developed a follicle greater than 10 mm diameter. Ovarian steroid hormone levels, Hoogland scores and bleeding patterns were not statistically significant between the groups. In contrast to prior studies, this analysis suggests no difference in follicle development or bleeding patterns among women receiving a 21/7 or 24/4 regimen of a 20-mcg EE/1-mg norethindrone acetate COC.
Abstract Background Combined oral contraceptive (COC) formulations with 20 mcg ethinyl estradiol (EE) have a greater incidence of ovarian hormone production and follicular development, which can be managed by shortening the number of hormone-free days per COC cycle. This study evaluates differences in follicular development during a 7-day versus 4-day hormone-free interval in a COC regimen with 20 mcg EE and 1 mg norethindrone acetate. Study Design Forty-one healthy women were randomized in an open-label fashion to this formulation in either a 24/4 or a 21/7 day regimen for three cycles. Estradiol, progesterone, follicle-stimulating hormone, luteinizing hormone and inhibin B were measured daily from Cycle 2, Day 21 to Cycle 3, Day 3 and on Day 7 of Cycle 3. Follicular diameter and Hoogland score were calculated on Cycle 2, Days 21, 24 and 28 and Cycle 3, Days 3 and 7. Results Sixty-six percent of subjects in the 21/7 group and 70% of the subjects in the 24/4 group developed a follicle greater than 10 mm diameter. Ovarian steroid hormone levels, Hoogland scores and bleeding patterns were not statistically significant between the groups. Conclusion In contrast to prior studies, this analysis suggests no difference in follicle development or bleeding patterns among women receiving a 21/7 or 24/4 regimen of a 20-mcg EE/1-mg norethindrone acetate COC.
Author Wilson, Melissa L.
Taylor, DeShawn
Mishell, Daniel R.
Rible, Radhika D.
Stanczyk, Frank Z.
Author_xml – sequence: 1
  givenname: Radhika D.
  surname: Rible
  fullname: Rible, Radhika D.
  email: r.rible@gmail.com
– sequence: 2
  givenname: DeShawn
  surname: Taylor
  fullname: Taylor, DeShawn
– sequence: 3
  givenname: Melissa L.
  surname: Wilson
  fullname: Wilson, Melissa L.
– sequence: 4
  givenname: Frank Z.
  surname: Stanczyk
  fullname: Stanczyk, Frank Z.
– sequence: 5
  givenname: Daniel R.
  surname: Mishell
  fullname: Mishell, Daniel R.
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21151254$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/19185670$$D View this record in MEDLINE/PubMed
BookMark eNqNktuKFDEQhhtZcWdXX0EConc9VtKdPiAIy7CrwoIX6nVIJzUzGdPJmHS3zOv4pGYOnhaEuQpF_f-XSv25yi6cd5hlLyjMKdDq9WauvBuCVLgdjHdzBtCkzhyAP8pmtKnbHDhtLrIZAIW8blh5mV3FuAGAuuX1k-yStrThVQ2z7Medt9ao0cpANE5o_bZHNxDjiCR1ruWOTBjiGEl5KNY-9GmcfBkQk2jAMElLvpthTaQjPqTir-kmPFTSOONWhAHp1YrgsDZuZwnGJNPG2-TUhJJ-RZwPh64O6Q6SGIMc8Gn2eCltxGen8zr7cnf7efE-v__47sPi5j5XnFVDrtqOF6ixYgyXlBUci6KqZdE2LddatVCVnaqhRihp18kiHW3Xyg4Z1JxpKK6zV0fuNvhvY5pO9CYqtFY69GMUVdUkOy-S8PlJOHY9arENppdhJ35tNQlengQyKmmXQTpl4m8do5RTxsuke3PUqeBjDLj8gwKxz1psxD9Zi33W-2bKOrlvHriVSfsyB4OxZzJujwxMi50MBhGVQadQm4BqENqbMzlvH3CUTaGnx3_FHcaNH4NL2QkqIhMgPu1_5v5jQgNQNhVNgMX_AWeP8RPoU_6X
CODEN CCPTAY
CitedBy_id crossref_primary_10_1136_bmjsrh_2018_CHC
crossref_primary_10_1177_0024363918815611
crossref_primary_10_3109_13625187_2014_979282
crossref_primary_10_1016_j_contraception_2012_12_006
crossref_primary_10_1146_annurev_pharmtox_031120_015212
crossref_primary_10_1007_s00404_012_2545_6
crossref_primary_10_15585_mmwr_rr7303a1
crossref_primary_10_1016_j_rbmo_2016_07_010
crossref_primary_10_1093_aje_kwq388
crossref_primary_10_1093_humrep_dev115
crossref_primary_10_1136_bmjsem_2021_001047
crossref_primary_10_1136_jfprhc_2013_100600
crossref_primary_10_1016_j_ajog_2012_04_022
crossref_primary_10_1097_AOG_0b013e3181e79440
Cites_doi 10.3109/13625189909043474
10.1080/ejc.6.2.108.114
10.1016/S0010-7824(02)00344-X
10.1095/biolreprod.103.017772
10.1016/0010-7824(93)90025-3
10.1016/j.contraception.2006.02.006
10.1016/j.contraception.2004.05.013
10.1016/S0010-7824(97)00174-1
10.1016/S0002-9378(98)70292-3
10.1080/gye.17.2.107.114
10.1016/j.maturitas.2004.01.001
10.1016/0002-9378(77)90733-5
10.1016/0010-7824(96)00137-0
10.1016/S0010-7824(99)00025-6
10.1016/S0015-0282(99)00205-8
10.1016/S0010-7824(99)00094-3
10.1016/S0002-9378(99)70364-9
10.1016/j.contraception.2004.05.006
10.1016/S0010-7824(97)00157-1
10.1016/S0029-7844(99)00524-4
10.1016/j.contraception.2006.08.004
10.1016/S0010-7824(01)00235-9
10.1016/j.steroids.2003.08.003
10.1016/j.contraception.2005.08.021
10.1016/S0010-7824(00)00098-6
10.1016/j.contraception.2007.01.014
10.1097/01.AOG.0000175834.77215.2e
10.1016/j.contraception.2004.12.012
ContentType Journal Article
Copyright 2009 Elsevier Inc.
Elsevier Inc.
2009 INIST-CNRS
Copyright_xml – notice: 2009 Elsevier Inc.
– notice: Elsevier Inc.
– notice: 2009 INIST-CNRS
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.contraception.2008.10.005
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic



MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1879-0518
EndPage 188
ExternalDocumentID 19185670
21151254
10_1016_j_contraception_2008_10_005
S0010782408004861
1_s2_0_S0010782408004861
Genre Comparative Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
--K
--M
.1-
.FO
.GJ
.~1
0R~
1B1
1P~
1RT
1~.
1~5
29F
3O-
4.4
457
4G.
53G
5GY
5RE
5VS
6PF
7-5
71M
8P~
9JM
AABNK
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AATTM
AAWTL
AAXKI
AAXUO
AAYWO
ABBQC
ABFNM
ABJNI
ABLJU
ABMAC
ABMZM
ABWVN
ABXDB
ACDAQ
ACGFS
ACIEU
ACIUM
ACLOT
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
ADVLN
AEBSH
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFFNX
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGHFR
AGQPQ
AGUBO
AGYEJ
AHHHB
AI.
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CS3
DU5
EBS
EFJIC
EFKBS
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HEC
HMK
HMO
HVGLF
HZ~
IHE
J1W
KOM
M29
M2X
M41
MO0
N9A
O-L
O9-
OAUVE
OQ.
OZT
P-8
P-9
P2P
PC.
PH~
Q38
R2-
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SEL
SES
SEW
SPCBC
SSH
SSZ
T5K
VH1
WUQ
Z5R
ZGI
~G-
~HD
AACTN
AFCTW
AFKWA
AJOXV
AMFUW
RIG
0SF
AAIAV
AAYXX
CITATION
AGCQF
AGRNS
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c526t-c9b53ede622ef1235e3367a39895ddc9064bc707e041bba30419b9abe20752d03
IEDL.DBID AIKHN
ISSN 0010-7824
1879-0518
IngestDate Thu Oct 02 11:43:57 EDT 2025
Wed Feb 19 01:44:03 EST 2025
Mon Jul 21 09:14:01 EDT 2025
Thu Apr 24 23:11:02 EDT 2025
Wed Oct 01 03:39:50 EDT 2025
Tue Jul 09 07:17:48 EDT 2024
Sun Feb 23 10:18:56 EST 2025
Tue Oct 14 19:37:00 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Oral contraceptive
Shortened hormone-free interval
Follicular development
Ethinylestradiol
Human
Estrogen
Oral administration
Administration schedule
Ovulation
Progestagen
Follicular phase
Dose activity relation
Treatment withdrawal
Female
Contraceptive
Norethisterone
Woman
Comparative study
Interval
Language English
License https://www.elsevier.com/tdm/userlicense/1.0
CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c526t-c9b53ede622ef1235e3367a39895ddc9064bc707e041bba30419b9abe20752d03
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
PMID 19185670
PQID 66870753
PQPubID 23479
PageCount 7
ParticipantIDs proquest_miscellaneous_66870753
pubmed_primary_19185670
pascalfrancis_primary_21151254
crossref_primary_10_1016_j_contraception_2008_10_005
crossref_citationtrail_10_1016_j_contraception_2008_10_005
elsevier_sciencedirect_doi_10_1016_j_contraception_2008_10_005
elsevier_clinicalkeyesjournals_1_s2_0_S0010782408004861
elsevier_clinicalkey_doi_10_1016_j_contraception_2008_10_005
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2009-03-01
PublicationDateYYYYMMDD 2009-03-01
PublicationDate_xml – month: 03
  year: 2009
  text: 2009-03-01
  day: 01
PublicationDecade 2000
PublicationPlace New York, NY
PublicationPlace_xml – name: New York, NY
– name: United States
PublicationTitle Contraception (Stoneham)
PublicationTitleAlternate Contraception
PublicationYear 2009
Publisher Elsevier Inc
Elsevier
Publisher_xml – name: Elsevier Inc
– name: Elsevier
References Baerwald, Olatunbosun, Pierson (bib6) 2004; 70
Spona, Elstien, Feichtinger (bib23) 1996; 54
Bachmann, Sulak, Sampson-Landers, Benda, Marr (bib20) 2004; 70
Van Heusden, Fauser (bib1) 1999; 59
Elomaa, Lähteenmäki (bib4) 1999; 60
Mishell (bib22) 2005; 71
Kuhnz, Huener, Humpel, Seifert, Michaelis (bib28) 1997; 56
Coffee, Sulak, Kuehl (bib16) 2007; 75
Pearlstein, Bachmann, Zacur, Yonkers (bib21) 2005; 72
Hite, Bannemerschult, Fox-Kuchenbecker, Turck, Brill (bib3) 1999; 4
Hoogland, Skouby (bib11) 1993; 47
Endrikat, Gerlinger, Plettig (bib12) 2003; 17
Sitruk-Ware (bib27) 2004; 47
Vree, Schmidt (bib18) 2001; 6
Grimes, Godwin, Rubin, Smith, Lacarra (bib8) 1994; 83
Baerwald, Adams, Pierson (bib10) 2003; 69
Nakajima, Archer, Ellman (bib17) 2007; 75
Bannemerschult, Hanker, Wünsch (bib2) 1997; 56
Jain, Ota, Mishell (bib7) 2000; 61
Willis, Kuehl, Spiekerman, Sulak (bib25) 2006; 74
Endrikat, Cronin, Gerlinger, Reubig, Schmidt, Düsterberg (bib29) 2001; 64
Brenner, Mishell, Stanczyk, Gobelsmann (bib14) 1977; 129
Stanczyk (bib26) 2003; 68
Killick, Fitzgerald, Davis (bib19) 1998; 179
Sullivan, Furniss, Spona, Elstein (bib24) 1999; 72
Sulak, Scow, Preece, Riggs, Kuehl (bib13) 2000; 95
Coney, Del Conte (bib9) 1999; 181
Creinin, Lippman, Eder, Godwin, Olson (bib5) 2002; 66
Yonkers, Brown, Pearlstein, Foegh, Sampson-Landers, Rapkin (bib15) 2005; 106
Sullivan (10.1016/j.contraception.2008.10.005_bib24) 1999; 72
Jain (10.1016/j.contraception.2008.10.005_bib7) 2000; 61
Creinin (10.1016/j.contraception.2008.10.005_bib5) 2002; 66
Baerwald (10.1016/j.contraception.2008.10.005_bib6) 2004; 70
Yonkers (10.1016/j.contraception.2008.10.005_bib15) 2005; 106
Grimes (10.1016/j.contraception.2008.10.005_bib8) 1994; 83
Sulak (10.1016/j.contraception.2008.10.005_bib13) 2000; 95
Bachmann (10.1016/j.contraception.2008.10.005_bib20) 2004; 70
Killick (10.1016/j.contraception.2008.10.005_bib19) 1998; 179
Bannemerschult (10.1016/j.contraception.2008.10.005_bib2) 1997; 56
Spona (10.1016/j.contraception.2008.10.005_bib23) 1996; 54
Nakajima (10.1016/j.contraception.2008.10.005_bib17) 2007; 75
Van Heusden (10.1016/j.contraception.2008.10.005_bib1) 1999; 59
Endrikat (10.1016/j.contraception.2008.10.005_bib29) 2001; 64
Coney (10.1016/j.contraception.2008.10.005_bib9) 1999; 181
Brenner (10.1016/j.contraception.2008.10.005_bib14) 1977; 129
Willis (10.1016/j.contraception.2008.10.005_bib25) 2006; 74
Hite (10.1016/j.contraception.2008.10.005_bib3) 1999; 4
Sitruk-Ware (10.1016/j.contraception.2008.10.005_bib27) 2004; 47
Mishell (10.1016/j.contraception.2008.10.005_bib22) 2005; 71
Coffee (10.1016/j.contraception.2008.10.005_bib16) 2007; 75
Elomaa (10.1016/j.contraception.2008.10.005_bib4) 1999; 60
Kuhnz (10.1016/j.contraception.2008.10.005_bib28) 1997; 56
Endrikat (10.1016/j.contraception.2008.10.005_bib12) 2003; 17
Hoogland (10.1016/j.contraception.2008.10.005_bib11) 1993; 47
Vree (10.1016/j.contraception.2008.10.005_bib18) 2001; 6
Pearlstein (10.1016/j.contraception.2008.10.005_bib21) 2005; 72
Stanczyk (10.1016/j.contraception.2008.10.005_bib26) 2003; 68
Baerwald (10.1016/j.contraception.2008.10.005_bib10) 2003; 69
References_xml – volume: 56
  start-page: 379
  year: 1997
  end-page: 385
  ident: bib28
  article-title: In vivo conversion of norethisterone and norethisterone acetate to ethinyl estradiol in postmenopausal women
  publication-title: Contraception
– volume: 68
  start-page: 879
  year: 2003
  end-page: 890
  ident: bib26
  article-title: All progestins are not created equal
  publication-title: Steroids
– volume: 72
  start-page: 414
  year: 2005
  end-page: 421
  ident: bib21
  article-title: Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation
  publication-title: Contraception
– volume: 47
  start-page: 277
  year: 2004
  end-page: 283
  ident: bib27
  article-title: Pharmacological profile of progestins
  publication-title: Maturitas
– volume: 181
  start-page: S53
  year: 1999
  end-page: S58
  ident: bib9
  article-title: The effects on ovarian activity of a monophasic oral contraceptive with 100 mcg levonorgestrel and 20 mcg ethinyl estradiol
  publication-title: Am J Obstet Gynecol
– volume: 72
  start-page: 115
  year: 1999
  end-page: 120
  ident: bib24
  article-title: Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 mcg) and ethinyl estradiol (15 mcg) on ovarian activity
  publication-title: Fertil Steril
– volume: 179
  start-page: S18
  year: 1998
  end-page: S24
  ident: bib19
  article-title: Ovarian activity in women taking an oral contraceptive containing 20 microg ethinyl estradiol and 150 microg desogestrel: effects of low estrogen doses during the hormone-free interval
  publication-title: Am J Obstet Gynecol
– volume: 56
  start-page: 285
  year: 1997
  end-page: 290
  ident: bib2
  article-title: A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low-dose oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel over six treatment cycles
  publication-title: Contraception
– volume: 74
  start-page: 100
  year: 2006
  end-page: 103
  ident: bib25
  article-title: Greater inhibition of the pituitary–ovarian axis in oral contraceptive regimens with a shortened hormone-free interval
  publication-title: Contraception
– volume: 95
  start-page: 261
  year: 2000
  end-page: 266
  ident: bib13
  article-title: Hormone withdrawal symptoms in oral contraceptive users
  publication-title: Obstet Gynecol
– volume: 60
  start-page: 275
  year: 1999
  end-page: 279
  ident: bib4
  article-title: Ovulatory potential of preovulatory sized follicles during oral contraceptive treatment
  publication-title: Contraception
– volume: 71
  start-page: 304
  year: 2005
  end-page: 305
  ident: bib22
  article-title: Rationale for decreasing the number of days of the hormone-free interval with use of low-dose oral contraceptive formulations
  publication-title: Contraception
– volume: 6
  start-page: 108
  year: 2001
  end-page: 114
  ident: bib18
  article-title: A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany
  publication-title: Eur J Contracept Reprod Health Care
– volume: 47
  start-page: 583
  year: 1993
  end-page: 590
  ident: bib11
  article-title: Ultrasound evaluation of ovarian activity under oral contraceptives
  publication-title: Contraception
– volume: 61
  start-page: 195
  year: 2000
  end-page: 198
  ident: bib7
  article-title: Comparison of ovarian follicular activity during treatment with a monthly injectable contraceptive and a low-dose oral contraceptive
  publication-title: Contraception
– volume: 129
  start-page: 133
  year: 1977
  end-page: 140
  ident: bib14
  article-title: Serum levels of
  publication-title: Am J Obstet Gynecol
– volume: 70
  start-page: 371
  year: 2004
  end-page: 377
  ident: bib6
  article-title: Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use
  publication-title: Contraception
– volume: 54
  start-page: 71
  year: 1996
  end-page: 77
  ident: bib23
  article-title: Shorter pill-free interval in combined oral contraceptives decreases follicular development
  publication-title: Contraception
– volume: 66
  start-page: 147
  year: 2002
  end-page: 152
  ident: bib5
  article-title: The effect of extending the pill-free interval on follicular activity: triphasic norgestimate/35 mcg ethinyl estradiol versus monophasic levonorgestrel/20 mcg ethinyl estradiol
  publication-title: Contraception
– volume: 75
  start-page: 444
  year: 2007
  end-page: 449
  ident: bib16
  article-title: Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen
  publication-title: Contraception
– volume: 106
  start-page: 492
  year: 2005
  end-page: 501
  ident: bib15
  article-title: Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder
  publication-title: Am J Ob Gyn
– volume: 64
  start-page: 201
  year: 2001
  end-page: 207
  ident: bib29
  article-title: Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 mcg ethinyl estradiol and 75 mcg gestodene and a 21-day regimen with 20 mcg ethinyl estradiol and 150 mcg desogestrel
  publication-title: Contraception
– volume: 59
  start-page: 237
  year: 1999
  end-page: 243
  ident: bib1
  article-title: Activity of the pituitary–ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives
  publication-title: Contraception
– volume: 4
  start-page: 7
  year: 1999
  end-page: 13
  ident: bib3
  article-title: Large observational trial of a new low-dose oral contraceptive containing 20 μg ethinylestradiol and 100 μg levonorgestrel (Miranova®) in Germany
  publication-title: Eur J Contracep Reprod Health Care
– volume: 75
  start-page: 16
  year: 2007
  end-page: 22
  ident: bib17
  article-title: Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 mcg (Loestrin 24 Fe)
  publication-title: Contraception
– volume: 83
  start-page: 29
  year: 1994
  end-page: 34
  ident: bib8
  article-title: Ovulation and follicular development associated with three low-dose oral contraceptives: a randomized controlled trial
  publication-title: Obstet Gynecol
– volume: 70
  start-page: 191
  year: 2004
  end-page: 198
  ident: bib20
  article-title: Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 mcg ethinylestradiol and 3 mg drospirenone
  publication-title: Contraception
– volume: 69
  start-page: 1023
  year: 2003
  end-page: 1031
  ident: bib10
  article-title: Characteristics of ovarian follicular wave dynamics in women
  publication-title: Biol Reprod
– volume: 17
  start-page: 107
  year: 2003
  end-page: 114
  ident: bib12
  article-title: A meta-analysis on the correlation between ovarian activity and the incidence of intermenstrual bleeding during low-dose oral contraceptive use
  publication-title: Gynecol Endocrinol
– volume: 4
  start-page: 7
  year: 1999
  ident: 10.1016/j.contraception.2008.10.005_bib3
  article-title: Large observational trial of a new low-dose oral contraceptive containing 20 μg ethinylestradiol and 100 μg levonorgestrel (Miranova®) in Germany
  publication-title: Eur J Contracep Reprod Health Care
  doi: 10.3109/13625189909043474
– volume: 6
  start-page: 108
  year: 2001
  ident: 10.1016/j.contraception.2008.10.005_bib18
  article-title: A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany
  publication-title: Eur J Contracept Reprod Health Care
  doi: 10.1080/ejc.6.2.108.114
– volume: 66
  start-page: 147
  year: 2002
  ident: 10.1016/j.contraception.2008.10.005_bib5
  article-title: The effect of extending the pill-free interval on follicular activity: triphasic norgestimate/35 mcg ethinyl estradiol versus monophasic levonorgestrel/20 mcg ethinyl estradiol
  publication-title: Contraception
  doi: 10.1016/S0010-7824(02)00344-X
– volume: 69
  start-page: 1023
  year: 2003
  ident: 10.1016/j.contraception.2008.10.005_bib10
  article-title: Characteristics of ovarian follicular wave dynamics in women
  publication-title: Biol Reprod
  doi: 10.1095/biolreprod.103.017772
– volume: 47
  start-page: 583
  year: 1993
  ident: 10.1016/j.contraception.2008.10.005_bib11
  article-title: Ultrasound evaluation of ovarian activity under oral contraceptives
  publication-title: Contraception
  doi: 10.1016/0010-7824(93)90025-3
– volume: 74
  start-page: 100
  year: 2006
  ident: 10.1016/j.contraception.2008.10.005_bib25
  article-title: Greater inhibition of the pituitary–ovarian axis in oral contraceptive regimens with a shortened hormone-free interval
  publication-title: Contraception
  doi: 10.1016/j.contraception.2006.02.006
– volume: 70
  start-page: 191
  year: 2004
  ident: 10.1016/j.contraception.2008.10.005_bib20
  article-title: Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 mcg ethinylestradiol and 3 mg drospirenone
  publication-title: Contraception
  doi: 10.1016/j.contraception.2004.05.013
– volume: 56
  start-page: 379
  year: 1997
  ident: 10.1016/j.contraception.2008.10.005_bib28
  article-title: In vivo conversion of norethisterone and norethisterone acetate to ethinyl estradiol in postmenopausal women
  publication-title: Contraception
  doi: 10.1016/S0010-7824(97)00174-1
– volume: 179
  start-page: S18
  year: 1998
  ident: 10.1016/j.contraception.2008.10.005_bib19
  article-title: Ovarian activity in women taking an oral contraceptive containing 20 microg ethinyl estradiol and 150 microg desogestrel: effects of low estrogen doses during the hormone-free interval
  publication-title: Am J Obstet Gynecol
  doi: 10.1016/S0002-9378(98)70292-3
– volume: 17
  start-page: 107
  year: 2003
  ident: 10.1016/j.contraception.2008.10.005_bib12
  article-title: A meta-analysis on the correlation between ovarian activity and the incidence of intermenstrual bleeding during low-dose oral contraceptive use
  publication-title: Gynecol Endocrinol
  doi: 10.1080/gye.17.2.107.114
– volume: 47
  start-page: 277
  year: 2004
  ident: 10.1016/j.contraception.2008.10.005_bib27
  article-title: Pharmacological profile of progestins
  publication-title: Maturitas
  doi: 10.1016/j.maturitas.2004.01.001
– volume: 129
  start-page: 133
  year: 1977
  ident: 10.1016/j.contraception.2008.10.005_bib14
  article-title: Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel
  publication-title: Am J Obstet Gynecol
  doi: 10.1016/0002-9378(77)90733-5
– volume: 54
  start-page: 71
  year: 1996
  ident: 10.1016/j.contraception.2008.10.005_bib23
  article-title: Shorter pill-free interval in combined oral contraceptives decreases follicular development
  publication-title: Contraception
  doi: 10.1016/0010-7824(96)00137-0
– volume: 59
  start-page: 237
  year: 1999
  ident: 10.1016/j.contraception.2008.10.005_bib1
  article-title: Activity of the pituitary–ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives
  publication-title: Contraception
  doi: 10.1016/S0010-7824(99)00025-6
– volume: 72
  start-page: 115
  year: 1999
  ident: 10.1016/j.contraception.2008.10.005_bib24
  article-title: Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 mcg) and ethinyl estradiol (15 mcg) on ovarian activity
  publication-title: Fertil Steril
  doi: 10.1016/S0015-0282(99)00205-8
– volume: 60
  start-page: 275
  year: 1999
  ident: 10.1016/j.contraception.2008.10.005_bib4
  article-title: Ovulatory potential of preovulatory sized follicles during oral contraceptive treatment
  publication-title: Contraception
  doi: 10.1016/S0010-7824(99)00094-3
– volume: 181
  start-page: S53
  year: 1999
  ident: 10.1016/j.contraception.2008.10.005_bib9
  article-title: The effects on ovarian activity of a monophasic oral contraceptive with 100 mcg levonorgestrel and 20 mcg ethinyl estradiol
  publication-title: Am J Obstet Gynecol
  doi: 10.1016/S0002-9378(99)70364-9
– volume: 70
  start-page: 371
  year: 2004
  ident: 10.1016/j.contraception.2008.10.005_bib6
  article-title: Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use
  publication-title: Contraception
  doi: 10.1016/j.contraception.2004.05.006
– volume: 56
  start-page: 285
  year: 1997
  ident: 10.1016/j.contraception.2008.10.005_bib2
  article-title: A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low-dose oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel over six treatment cycles
  publication-title: Contraception
  doi: 10.1016/S0010-7824(97)00157-1
– volume: 95
  start-page: 261
  year: 2000
  ident: 10.1016/j.contraception.2008.10.005_bib13
  article-title: Hormone withdrawal symptoms in oral contraceptive users
  publication-title: Obstet Gynecol
  doi: 10.1016/S0029-7844(99)00524-4
– volume: 75
  start-page: 16
  year: 2007
  ident: 10.1016/j.contraception.2008.10.005_bib17
  article-title: Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 mcg (Loestrin 24 Fe)
  publication-title: Contraception
  doi: 10.1016/j.contraception.2006.08.004
– volume: 64
  start-page: 201
  year: 2001
  ident: 10.1016/j.contraception.2008.10.005_bib29
  article-title: Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 mcg ethinyl estradiol and 75 mcg gestodene and a 21-day regimen with 20 mcg ethinyl estradiol and 150 mcg desogestrel
  publication-title: Contraception
  doi: 10.1016/S0010-7824(01)00235-9
– volume: 68
  start-page: 879
  year: 2003
  ident: 10.1016/j.contraception.2008.10.005_bib26
  article-title: All progestins are not created equal
  publication-title: Steroids
  doi: 10.1016/j.steroids.2003.08.003
– volume: 72
  start-page: 414
  year: 2005
  ident: 10.1016/j.contraception.2008.10.005_bib21
  article-title: Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation
  publication-title: Contraception
  doi: 10.1016/j.contraception.2005.08.021
– volume: 61
  start-page: 195
  year: 2000
  ident: 10.1016/j.contraception.2008.10.005_bib7
  article-title: Comparison of ovarian follicular activity during treatment with a monthly injectable contraceptive and a low-dose oral contraceptive
  publication-title: Contraception
  doi: 10.1016/S0010-7824(00)00098-6
– volume: 83
  start-page: 29
  year: 1994
  ident: 10.1016/j.contraception.2008.10.005_bib8
  article-title: Ovulation and follicular development associated with three low-dose oral contraceptives: a randomized controlled trial
  publication-title: Obstet Gynecol
– volume: 75
  start-page: 444
  year: 2007
  ident: 10.1016/j.contraception.2008.10.005_bib16
  article-title: Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen
  publication-title: Contraception
  doi: 10.1016/j.contraception.2007.01.014
– volume: 106
  start-page: 492
  year: 2005
  ident: 10.1016/j.contraception.2008.10.005_bib15
  article-title: Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder
  publication-title: Am J Ob Gyn
  doi: 10.1097/01.AOG.0000175834.77215.2e
– volume: 71
  start-page: 304
  year: 2005
  ident: 10.1016/j.contraception.2008.10.005_bib22
  article-title: Rationale for decreasing the number of days of the hormone-free interval with use of low-dose oral contraceptive formulations
  publication-title: Contraception
  doi: 10.1016/j.contraception.2004.12.012
SSID ssj0007957
Score 1.9680411
Snippet Combined oral contraceptive (COC) formulations with 20 mcg ethinyl estradiol (EE) have a greater incidence of ovarian hormone production and follicular...
Abstract Background Combined oral contraceptive (COC) formulations with 20 mcg ethinyl estradiol (EE) have a greater incidence of ovarian hormone production...
SourceID proquest
pubmed
pascalfrancis
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 182
SubjectTerms Adolescent
Adult
Biological and medical sciences
Birth control
Contraceptives, Oral, Combined - administration & dosage
Drug Administration Schedule
Endometrium - drug effects
Estradiol - blood
Ethinyl Estradiol - administration & dosage
Female
Follicle Stimulating Hormone - blood
Follicular development
Genital system. Reproduction
Gynecology. Andrology. Obstetrics
Hormonal contraception
Humans
Inhibins - blood
Luteinizing Hormone - blood
Medical sciences
Menstruation - drug effects
Middle Aged
Norethindrone - administration & dosage
Norethindrone - analogs & derivatives
Obstetrics and Gynecology
Oral contraceptive
Ovarian Follicle - diagnostic imaging
Ovarian Follicle - drug effects
Ovarian Follicle - growth & development
Pharmacology. Drug treatments
Progesterone - blood
Shortened hormone-free interval
Ultrasonography
Young Adult
Title Follicular development in a 7-day versus 4-day hormone-free interval with an oral contraceptive containing 20 mcg ethinyl estradiol and 1 mg norethindrone acetate
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0010782408004861
https://www.clinicalkey.es/playcontent/1-s2.0-S0010782408004861
https://dx.doi.org/10.1016/j.contraception.2008.10.005
https://www.ncbi.nlm.nih.gov/pubmed/19185670
https://www.proquest.com/docview/66870753
Volume 79
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVESC
  databaseName: Elsevier SD Complete Freedom Collection [SCCMFC]
  customDbUrl:
  eissn: 1879-0518
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0007957
  issn: 0010-7824
  databaseCode: ACRLP
  dateStart: 19980701
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection
  customDbUrl:
  eissn: 1879-0518
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0007957
  issn: 0010-7824
  databaseCode: .~1
  dateStart: 19950101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: ScienceDirect Freedom Collection Journals
  customDbUrl:
  eissn: 1879-0518
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0007957
  issn: 0010-7824
  databaseCode: AIKHN
  dateStart: 19980701
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVLSH
  databaseName: Elsevier Journals
  customDbUrl:
  mediaType: online
  eissn: 1879-0518
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0007957
  issn: 0010-7824
  databaseCode: AKRWK
  dateStart: 19700101
  isFulltext: true
  providerName: Library Specific Holdings
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3ra9swEBddCmUwxp6d98gE21evfsiSPcaghIXsVcZYod-EZJ1bj9QJcTLol_0x-0t3suRkYSsE9snY5ixbj7vfWb-7I-Sl4SLJNbolRZ5qdFA0hApSFlagMgWZQWeuI8ie8Mkp-3CWne2RUR8LY2mVXvc7nd5pa3_lyPfm0byubYxvbO0bs5iH5dYF2kf7k-cDsn_8_uPkZK2QReESftp9XytwQF5saF4dI1x5ConjVnZsr-w6Q3VrrlrsvsrVvbgemHYGanyH3PbIkh67l79L9qC5Rw4--73z--TX2Obf7min1GyoQrRuqKIiNOqKWorGqqWsO7lANDtrIKwWALTuqJH4ePvflqqG2sB--sdX_YDuzNWboElEL8tzCsuLurmaUrD_U0w9m6KkoTG9PKeNDZ_Eu2aBbVB8hgW9D8jp-N230ST0FRrCMkv4MiwLnaVggCcJVDbqFtKUC5UWeZEZUxaId3QpIgERi7VWKR4KXSgNCSKVxETpQzJosJlHhKac8RJKrkWEPmdZoeNsFI8Nr5K84kwE5HU_HLL06cttFY2p7Hlq3-XWWLoCm7HNfpoFhK2F5y6Lx25ib_pxl32gKqpWidZmN3HxL3FovZpoZSzbREbyr6kckLdrya3VsHvTw61puv5q9PcR4mUsIM_7eStRodhdItXAbNVKzlGFoxMbkEM3nTc9ViC44yJ6_L9v94TcdJtylsr3lAyWixU8Q2y31ENy49XPeIgrePT105ehX8m_AWYyVS0
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1da9swFBWlg24wyj47d1sr2F692rI-4jEGoyxkW9unFvomJOu69UidECeDvuzH7JfuyrKTha0Q2FNwkmvZknx1jnXuvYS8dVKxgUVakg8yiwTFQmwg43EJRhgQDslcK5A9k6ML_vVSXG6R4z4WxssqO98ffHrrrbtvjrrePJpWlY_xTf36xj3m4QNPge5xwZRnYO9-rnQeKg_pPv2ur__7DnmzEnm1enDTCUiCsrLVeom7lqmHU9Ng55Wh6sXdsLRdnoaPyG6HK-mncOmPyRbUT8jOabdz_pT8Gvrs263olLqVUIhWNTVUxc7cUi_QWDSUtwfXiGUnNcTlDIBWrTAST-_f2lJTUx_WT_-4qx_QHoVqE5Ql9Ka4ojC_rurbMQX_NsVVkzFaOprSmyta--BJ_NXNsA2K5_CQ9xm5GH4-Px7FXX2GuBBMzuMityIDB5IxKH3MLWSZVCbLB7lwrsgR7dhCJQoSnlprMvzIbW4sMMQpzCXZc7JdYzMvCM0klwUU0qoEGWdRIm12RqZOlmxQSq4i8r4fDl10yct9DY2x7lVq3_XaWIbymqnPfSoiwpfG05DDYzOzD_246z5MFR2rxrVmM3P1L3NoOifR6FQ3TCf6r4kckY9Ly7VnYfOmD9am6fKuke0jwBM8Iof9vNXoTvwekalhsmi0lOjAkcJGZC9M51WP5QjtpEr2__fqDsn90fnpiT75cvbtJXkQtue8qO8V2Z7PFvAaUd7cHrRP8W-s61Rg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Follicular+development+in+a+7-day+versus+4-day+hormone-free+interval+with+an+oral+contraceptive+containing+20+mcg+ethinyl+estradiol+and+1+mg+norethindrone+acetate&rft.jtitle=Contraception+%28Stoneham%29&rft.au=Rible%2C+Radhika+D&rft.au=Taylor%2C+DeShawn&rft.au=Wilson%2C+Melissa+L&rft.au=Stanczyk%2C+Frank+Z&rft.date=2009-03-01&rft.issn=1879-0518&rft.eissn=1879-0518&rft.volume=79&rft.issue=3&rft.spage=182&rft_id=info:doi/10.1016%2Fj.contraception.2008.10.005&rft.externalDBID=NO_FULL_TEXT
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00107824%2FS0010782409X00028%2Fcov150h.gif